SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 224 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,689,500 | -13.4% | 133,823 | -5.5% | 0.00% | – |
| Q2 2023 | $4,259,021 | -44.5% | 141,684 | -33.1% | 0.00% | -100.0% |
| Q1 2023 | $7,673,000 | +88472.1% | 211,771 | -12.8% | 0.00% | 0.0% |
| Q4 2022 | $8,663 | -99.9% | 242,855 | +15.4% | 0.00% | 0.0% |
| Q3 2022 | $7,123,000 | -2.7% | 210,406 | -16.9% | 0.00% | 0.0% |
| Q2 2022 | $7,320,000 | +217.8% | 253,095 | +255.1% | 0.00% | – |
| Q1 2022 | $2,303,000 | +32.0% | 71,265 | +19.1% | 0.00% | – |
| Q4 2021 | $1,745,000 | +23.7% | 59,822 | +13.1% | 0.00% | – |
| Q3 2021 | $1,411,000 | -12.6% | 52,874 | +0.9% | 0.00% | – |
| Q2 2021 | $1,615,000 | +26.3% | 52,423 | +7.3% | 0.00% | – |
| Q1 2021 | $1,279,000 | -27.1% | 48,850 | -30.0% | 0.00% | – |
| Q4 2020 | $1,755,000 | +121.6% | 69,778 | +83.7% | 0.00% | – |
| Q3 2020 | $792,000 | -24.5% | 37,989 | -14.0% | 0.00% | – |
| Q2 2020 | $1,049,000 | +56.8% | 44,164 | +18.7% | 0.00% | – |
| Q1 2020 | $669,000 | -29.3% | 37,199 | -6.7% | 0.00% | – |
| Q4 2019 | $946,000 | +85.1% | 39,878 | +114.4% | 0.00% | – |
| Q3 2019 | $511,000 | -2.5% | 18,602 | +13.5% | 0.00% | – |
| Q2 2019 | $524,000 | +6.7% | 16,384 | +16.9% | 0.00% | – |
| Q1 2019 | $491,000 | -71.5% | 14,015 | -73.0% | 0.00% | – |
| Q4 2018 | $1,724,000 | -76.0% | 51,882 | -63.7% | 0.00% | -100.0% |
| Q3 2018 | $7,194,000 | -39.7% | 142,878 | -28.4% | 0.00% | -50.0% |
| Q2 2018 | $11,937,000 | -43.5% | 199,439 | -56.8% | 0.00% | -60.0% |
| Q1 2018 | $21,140,000 | +205.7% | 461,586 | +166.0% | 0.01% | +400.0% |
| Q4 2017 | $6,915,000 | +11620.3% | 173,527 | +11391.9% | 0.00% | – |
| Q3 2017 | $59,000 | -97.3% | 1,510 | -97.1% | 0.00% | -100.0% |
| Q2 2017 | $2,219,000 | -8.5% | 51,467 | -33.5% | 0.00% | 0.0% |
| Q1 2017 | $2,424,000 | +2.5% | 77,431 | -17.3% | 0.00% | 0.0% |
| Q4 2016 | $2,364,000 | +261.5% | 93,621 | +253.6% | 0.00% | – |
| Q3 2016 | $654,000 | +32600.0% | 26,475 | +31047.1% | 0.00% | – |
| Q2 2016 | $2,000 | -99.9% | 85 | -100.0% | 0.00% | -100.0% |
| Q1 2016 | $2,870,000 | +13.5% | 188,190 | +0.0% | 0.00% | 0.0% |
| Q4 2015 | $2,528,000 | – | 188,105 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |